Review Article
ACE Insertion/Deletion Polymorphism and Diabetic Nephropathy: Clinical Implications of Genetic Information
Table 2
Studies examining the association of the ACE I/D polymorphism and response to antiproteinuric (renoprotective) effect of ARB therapy.
| Authors (Year) | Ethnicity | Disease and patient number | Study durations (month) | Therapy drug | Effects on proteinuria or progression | Reference |
|
Andersen et al. (2002) | Caucasian | Type 1 DM (54) | 4 | Losartan | No differences in reduction of proteinuria | [50] |
Andersen et al. (2003) | Caucasian | Type 1 DM (54) | 36 | Losartan | No differences in reduction of proteinuria | [51] |
Haneda et al. (2004) | Asian (Japanese) | Type 2 DM (127) | 3 | Candesartan | No differences in reduction of proteinuria | [52] | Parving et al. (2008) | Mixed | Type 2 DM (1435) | 40.8 | Losartan | DD genotype more risk reduction reaching ESRD | [53] | Cheema et al. (2013) | Asian (Indian) | Type 2 DM (320) | 36 | ARBs | DD genotype associated with better renoprotective response | [49] |
|
|
ARB: angiotensin receptor blocker; ACE I/D polymorphism: angiotensin converting enzyme insertion/deletion polymorphism.
|